Vanguard Group’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-221,371
| Closed | -$4.07M | – | 4361 |
|
|
2020
Q4 | $4.07M | Buy |
221,371
+5,115
| +2% | +$93.2K | ﹤0.01% | 3449 |
|
|
2020
Q3 | $3.97M | Sell |
216,256
-1,038
| -0.5% | -$17.4K | ﹤0.01% | 3268 |
|
|
2020
Q2 | $3.25M | Buy |
217,294
+6,685
| +3% | +$95.5K | ﹤0.01% | 3279 |
|
|
2020
Q1 | $3.33M | Buy |
210,609
+234
| +0.1% | +$3.78K | ﹤0.01% | 3148 |
|
|
2019
Q4 | $3.42M | Sell |
210,375
-2,042
| -1% | -$34.1K | ﹤0.01% | 3294 |
|
|
2019
Q3 | $3.16M | Buy |
212,417
+1,245
| +0.6% | +$16.8K | ﹤0.01% | 3287 |
|
|
2019
Q2 | $3.49M | Sell |
211,172
-3,461
| -2% | -$56.5K | ﹤0.01% | 3293 |
|
|
2019
Q1 | $3.71M | Buy |
214,633
+21,152
| +11% | +$384K | ﹤0.01% | 3247 |
|
|
2018
Q4 | $3.42M | Buy |
193,481
+9,653
| +5% | +$164K | ﹤0.01% | 3212 |
|
|
2018
Q3 | $3.34M | Buy |
183,828
+7,443
| +4% | +$153K | ﹤0.01% | 3369 |
|
|
2018
Q2 | $3.45M | Buy |
176,385
+34,352
| +24% | +$644K | ﹤0.01% | 3338 |
|
|
2018
Q1 | $2.49M | Buy |
142,033
+58,962
| +71% | +$1.08M | ﹤0.01% | 3383 |
|
|
2017
Q4 | $943K | Hold |
83,071
| – | – | ﹤0.01% | 3624 |
|
|
2017
Q3 | $885K | Sell |
83,071
-6,480
| -7% | -$61.3K | ﹤0.01% | 3617 |
|
|
2017
Q2 | $783K | Sell |
89,551
-30,059
| -25% | -$265K | ﹤0.01% | 3629 |
|
|
2017
Q1 | $1.41M | Buy |
119,610
+228
| +0.2% | +$2.77K | ﹤0.01% | 3488 |
|
|
2016
Q4 | $1.56M | Buy |
119,382
+10,359
| +10% | +$139K | ﹤0.01% | 3445 |
|
|
2016
Q3 | $1.58M | Buy |
109,023
+5,608
| +5% | +$79.6K | ﹤0.01% | 3460 |
|
|
2016
Q2 | $1.24M | Buy |
103,415
+1,541
| +2% | +$24.8K | ﹤0.01% | 3541 |
|
|
2016
Q1 | $1.9M | Buy |
101,874
+28,520
| +39% | +$473K | ﹤0.01% | 3401 |
|
|
2015
Q4 | $1.58M | Buy |
73,354
+12,978
| +21% | +$274K | ﹤0.01% | 3485 |
|
|
2015
Q3 | $1.02M | Buy |
60,376
+23,941
| +66% | +$595K | ﹤0.01% | 3624 |
|
|
2015
Q2 | $1.37M | Buy |
36,435
+27,824
| +323% | +$898K | ﹤0.01% | 3563 |
|
|
2015
Q1 | $271K | Buy |
+8,611
| New | +$233K | ﹤0.01% | 3949 |
|
Vanguard Group's CBMG Position: Q1 2021 in Review
Vanguard Group sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q1 2021, closing a stake of 221,371 shares — an estimated $4.07M sold.
Vanguard Group first reported a position in CBMG in Q1 2015 and held it in 24 quarters. The position peaked at $4.07M in Q4 2020. 0 funds tracked by Wall St. Rank hold CBMG as of Q1 2021.
- Vanguard Group reported no remaining Cellular Biomedicine Group, Inc. position as of Q1 2021 after selling out during the quarter.
- Vanguard Group sold 221,371 Cellular Biomedicine Group, Inc. shares in Q1 2021, an estimated $4.07M.
- Vanguard Group first reported a position in Cellular Biomedicine Group, Inc. in Q1 2015 and held it in 24 quarters.
- Vanguard Group's Cellular Biomedicine Group, Inc. position peaked at $4.07M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q1 2021.
Based on Vanguard Group's 13F filing for Q1 2021, filed 14 May 2021.